CR20220541A - Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos - Google Patents

Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos

Info

Publication number
CR20220541A
CR20220541A CR20220541A CR20220541A CR20220541A CR 20220541 A CR20220541 A CR 20220541A CR 20220541 A CR20220541 A CR 20220541A CR 20220541 A CR20220541 A CR 20220541A CR 20220541 A CR20220541 A CR 20220541A
Authority
CR
Costa Rica
Prior art keywords
binding
antigen
dll3
binding molecules
molecules
Prior art date
Application number
CR20220541A
Other languages
English (en)
Spanish (es)
Inventor
Shu Wen Samantha Ho
Tomoyuki Igawa
Sotaro Naoi
Shu Feng
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CR20220541A publication Critical patent/CR20220541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CR20220541A 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos CR20220541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020062326 2020-03-31
PCT/JP2021/013460 WO2021200898A1 (en) 2020-03-31 2021-03-30 Dll3-targeting multispecific antigen-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
CR20220541A true CR20220541A (es) 2022-11-28

Family

ID=77855554

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20220541A CR20220541A (es) 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
CR20250287A CR20250287A (es) 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta (dll3) y sus usos (divisional exp. 2022-0541)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20250287A CR20250287A (es) 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta (dll3) y sus usos (divisional exp. 2022-0541)

Country Status (19)

Country Link
US (3) US11274151B2 (enExample)
EP (1) EP4126969A4 (enExample)
JP (2) JP7085666B2 (enExample)
KR (2) KR20230035138A (enExample)
CN (1) CN115397866B (enExample)
AR (1) AR121695A1 (enExample)
AU (1) AU2021250186A1 (enExample)
BR (1) BR112022019498A2 (enExample)
CA (1) CA3173587A1 (enExample)
CL (1) CL2022002624A1 (enExample)
CO (1) CO2022015305A2 (enExample)
CR (2) CR20220541A (enExample)
IL (1) IL296803A (enExample)
MX (1) MX2022012091A (enExample)
PE (1) PE20230077A1 (enExample)
PH (1) PH12022500013A1 (enExample)
SG (1) SG11202105302PA (enExample)
TW (1) TWI799824B (enExample)
WO (1) WO2021200898A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3070168B1 (en) 2013-11-11 2024-07-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
WO2016076345A1 (ja) 2014-11-11 2016-05-19 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子のライブラリ
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
WO2020027330A1 (ja) 2018-08-03 2020-02-06 中外製薬株式会社 互いに連結された２つの抗原結合ドメインを含む抗原結合分子
AU2021250381A1 (en) * 2020-03-31 2022-10-06 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules
WO2021200898A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
JP7557922B2 (ja) 2021-09-29 2024-09-30 中外製薬株式会社 Ｄｌｌ３標的多重特異性抗原結合分子の使用
JP2025508786A (ja) 2022-02-23 2025-04-10 アムジェン インコーポレイテッド Ｄｌｌ３を標的とする癌治療
TW202436348A (zh) 2022-11-25 2024-09-16 日商中外製藥股份有限公司 蛋白質的製造方法
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
TW202509075A (zh) 2023-05-19 2025-03-01 德商百靈佳殷格翰國際股份有限公司 T細胞銜接蛋白治療癌症之用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0328966Y2 (enExample) 1987-10-16 1991-06-20
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
JP4332581B2 (ja) 1998-02-19 2009-09-16 旭化成株式会社 ヒトデルタ−３
JP4139508B2 (ja) 1998-02-19 2008-08-27 旭化成株式会社 ヒトデルター３
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
CA2361293A1 (en) 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
AU6913100A (en) 1999-08-19 2001-03-13 Chiron Corporation Notch receptor ligands and uses thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
WO2002014358A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Novel secreted proteins and their uses
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
JP2006516089A (ja) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DK1709081T3 (da) 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
EP2940043A1 (en) 2004-07-15 2015-11-04 Xencor, Inc. Optimized fc variants
MX2007003320A (es) 2004-09-24 2007-05-18 Amgen Inc Moleculas fc modificadas.
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN101123983A (zh) 2004-10-27 2008-02-13 米迪缪尼股份有限公司 特定修饰对相关抗原的亲和力来调节抗体的特异性
EP2028193B1 (en) 2005-01-05 2012-03-07 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
WO2006083706A2 (en) 2005-01-31 2006-08-10 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
WO2010080538A1 (en) 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
CN101336300A (zh) 2005-12-16 2008-12-31 健泰科生物技术公司 神经胶质瘤的诊断、预后和治疗方法
EP2216339A1 (en) 2006-01-16 2010-08-11 Compugen Ltd. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
CN101466733A (zh) 2006-04-14 2009-06-24 特鲁比昂药品公司 包含免疫球蛋白铰链区和Fc效应子功能改变了的Fc区的结合蛋白
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
CN103694350B (zh) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2009099961A2 (en) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
CA2734905A1 (en) 2008-09-03 2010-03-11 Jenny M. Bostrom Multispecific antibodies
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
HUE038962T2 (hu) 2010-01-29 2018-12-28 Chugai Pharmaceutical Co Ltd DLL3-ellenes antitest
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
EP2663334A4 (en) 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
TWI687441B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
US20130058936A1 (en) 2011-08-23 2013-03-07 Peter Bruenker Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
KR102492792B1 (ko) 2011-10-11 2023-01-30 제넨테크, 인크. 이중특이적 항체의 개선된 어셈블리
BR112014008849A2 (pt) 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
NZ628804A (en) 2012-02-24 2017-08-25 Abbvie Stemcentrx Llc Dll3 modulators and methods of use
CN107759686A (zh) 2012-05-30 2018-03-06 中外制药株式会社 靶组织特异性抗原结合分子
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
KR102249779B1 (ko) 2012-12-27 2021-05-07 추가이 세이야쿠 가부시키가이샤 헤테로이량화 폴리펩티드
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP3070168B1 (en) 2013-11-11 2024-07-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
EA201691827A1 (ru) 2014-03-12 2017-01-30 Новартис Аг Конкретные участки для модификации антител с целью получения иммуноконъюгатов
JPWO2015146438A1 (ja) 2014-03-26 2017-04-13 国立大学法人東北大学 ヒト上皮増殖因子受容体を標的とした二重特異性抗体
CA2943943C (en) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
EP3174901B1 (en) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
MX384418B (es) 2014-07-31 2025-03-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
WO2016076345A1 (ja) 2014-11-11 2016-05-19 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子のライブラリ
EP3305322A4 (en) 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
PL3115376T3 (pl) 2015-07-10 2019-01-31 Merus N.V. Ludzkie przeciwciało wiążące cd3
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
BR112018069890A2 (pt) 2016-05-02 2019-02-05 Hoffmann La Roche polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
AU2017380981B2 (en) 2016-12-19 2025-01-30 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1BB (CD137) agonists
IL267406B2 (en) 2016-12-20 2025-05-01 Hoffmann La Roche Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
UY37726A (es) 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2020027330A1 (ja) 2018-08-03 2020-02-06 中外製薬株式会社 互いに連結された２つの抗原結合ドメインを含む抗原結合分子
JP2022501325A (ja) 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
KR20210068079A (ko) 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
CN113166263A (zh) * 2018-10-11 2021-07-23 印希比股份有限公司 Dll3单域抗体及其治疗性组合物
AU2021215622A1 (en) 2020-02-05 2022-07-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing and/or enriching recombinant antigen-binding molecules
WO2021200898A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
AU2021250381A1 (en) 2020-03-31 2022-10-06 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules

Also Published As

Publication number Publication date
AR121695A1 (es) 2022-06-29
KR20220100520A (ko) 2022-07-15
TWI799824B (zh) 2023-04-21
MX2022012091A (es) 2022-10-13
EP4126969A4 (en) 2024-05-29
PH12022500013A1 (en) 2023-09-11
US20240010725A1 (en) 2024-01-11
SG11202105302PA (en) 2021-11-29
US20220251201A1 (en) 2022-08-11
CL2022002624A1 (es) 2023-06-02
US20210301016A1 (en) 2021-09-30
TW202325741A (zh) 2023-07-01
CN115397866A (zh) 2022-11-25
JP2022122972A (ja) 2022-08-23
IL296803A (en) 2022-11-01
CO2022015305A2 (es) 2022-11-08
US11718672B2 (en) 2023-08-08
WO2021200898A1 (en) 2021-10-07
CN115397866B (zh) 2025-10-31
KR20230035138A (ko) 2023-03-10
KR102505383B1 (ko) 2023-03-02
US11274151B2 (en) 2022-03-15
PE20230077A1 (es) 2023-01-11
AU2021250186A1 (en) 2022-12-01
JP7085666B2 (ja) 2022-06-16
TW202204409A (zh) 2022-02-01
EP4126969A1 (en) 2023-02-08
BR112022019498A2 (pt) 2022-11-16
CA3173587A1 (en) 2021-10-07
JP2021159081A (ja) 2021-10-11
CR20250287A (es) 2025-08-28

Similar Documents

Publication Publication Date Title
CR20220541A (es) Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
ECSP18076028A (es) Moléculas de unión b7-h3 novedosas, conjugados anticuerpo-fármaco de los mismos y métodos de uso de los mismos
CL2021002241A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
AR114550A1 (es) Moléculas de unión al antígeno anti-cd137 y sus usos
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
CO2024006160A2 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
CL2023002099A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
MX2024003713A (es) Usos de moleculas de union al antigeno multiespecificas dirigidas al ligando tipo delta 3 (dll3).
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
MX390484B (es) Construcción biespecífica que se une a cd33 y cd3 para usarse en tratamiento de leucemia mieloide
UY38520A (es) Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos
MX2022001682A (es) Nuevos formatos de moleculas de union a antigenos.
CL2022002150A1 (es) Moléculas de unión a antígeno anti-cd137 para su administración en el tratamiento contra el cáncer
CY1122357T1 (el) Αντικαρκινικος συνδυασμος που περιλαμβανει καμπαζιταξελη και σισπλατινη
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
BR112022013566A2 (pt) Compostos para distúrbios crônicos
AR122120A1 (es) Moléculas de fijación para el tratamiento de cáncer
AR121314A1 (es) Moléculas de unión a antígeno anti-cd137 para su administración en el tratamiento contra el cáncer
AR121696A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos